158 related articles for article (PubMed ID: 3485267)
1. Neural mechanisms mediating 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced parkinsonism in the monkey: relative contributions of the striatopallidal and striatonigral pathways as suggested by 2-deoxyglucose uptake.
Mitchell IJ; Cross AJ; Sambrook MA; Crossman AR
Neurosci Lett; 1986 Jan; 63(1):61-5. PubMed ID: 3485267
[TBL] [Abstract][Full Text] [Related]
2. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Mitchell IJ; Clarke CE; Boyce S; Robertson RG; Peggs D; Sambrook MA; Crossman AR
Neuroscience; 1989; 32(1):213-26. PubMed ID: 2586750
[TBL] [Abstract][Full Text] [Related]
3. Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the macaque monkey.
Crossman AR; Mitchell IJ; Sambrook MA
Neuropharmacology; 1985 Jun; 24(6):587-91. PubMed ID: 3875056
[TBL] [Abstract][Full Text] [Related]
4. Neural mechanisms of dystonia: evidence from a 2-deoxyglucose uptake study in a primate model of dopamine agonist-induced dystonia.
Mitchell IJ; Luquin R; Boyce S; Clarke CE; Robertson RG; Sambrook MA; Crossman AR
Mov Disord; 1990; 5(1):49-54. PubMed ID: 2296259
[TBL] [Abstract][Full Text] [Related]
5. N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the monkey: neurochemical pathology and regional brain metabolism.
Mitchell IJ; Cross AJ; Sambrook MA; Crossman AR
J Neural Transm Suppl; 1986; 20():41-6. PubMed ID: 3462325
[TBL] [Abstract][Full Text] [Related]
6. Changes in the local cerebral metabolic rate for glucose in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate model of Parkinson's disease.
Schwartzman RJ; Alexander GM
Brain Res; 1985 Dec; 358(1-2):137-43. PubMed ID: 3878182
[TBL] [Abstract][Full Text] [Related]
7. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia.
Mitchell IJ; Boyce S; Sambrook MA; Crossman AR
Brain; 1992 Jun; 115 ( Pt 3)():809-24. PubMed ID: 1628204
[TBL] [Abstract][Full Text] [Related]
8. Hemiparkinsonism in monkeys after unilateral caudate nucleus infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): behavior and histology.
Imai H; Nakamura T; Endo K; Narabayashi H
Brain Res; 1988 Dec; 474(2):327-32. PubMed ID: 3264746
[TBL] [Abstract][Full Text] [Related]
9. An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
Waters CM; Hunt SP; Jenner P; Marsden CD
Neuroscience; 1987 Dec; 23(3):1025-39. PubMed ID: 2893993
[TBL] [Abstract][Full Text] [Related]
10. Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys.
Tsukahara T; Takeda M; Shimohama S; Ohara O; Hashimoto N
Neurosurgery; 1995 Oct; 37(4):733-9; discussion 739-41. PubMed ID: 8559303
[TBL] [Abstract][Full Text] [Related]
11. Lesions in monkey globus pallidus externus exacerbate parkinsonian symptoms.
Zhang J; Russo GS; Mewes K; Rye DB; Vitek JL
Exp Neurol; 2006 Jun; 199(2):446-53. PubMed ID: 16487515
[TBL] [Abstract][Full Text] [Related]
12. The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: evidence from [3H]flunitrazepam autoradiography.
Robertson RG; Clarke CA; Boyce S; Sambrook MA; Crossman AR
Brain Res; 1990 Oct; 531(1-2):95-104. PubMed ID: 2289139
[TBL] [Abstract][Full Text] [Related]
13. Changes in local cerebral glucose utilization associated with Parkinson's syndrome induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the primate.
Porrino LJ; Burns RS; Crane AM; Palombo E; Kopin IJ; Sokoloff L
Life Sci; 1987 Apr; 40(17):1657-64. PubMed ID: 3494179
[TBL] [Abstract][Full Text] [Related]
14. Neurons in the globus pallidus do not show correlated activity in the normal monkey, but phase-locked oscillations appear in the MPTP model of parkinsonism.
Nini A; Feingold A; Slovin H; Bergman H
J Neurophysiol; 1995 Oct; 74(4):1800-5. PubMed ID: 8989416
[TBL] [Abstract][Full Text] [Related]
15. Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration.
Ghorayeb I; Fernagut PO; Aubert I; Bezard E; Poewe W; Wenning GK; Tison F
Mov Disord; 2000 May; 15(3):531-6. PubMed ID: 10830420
[TBL] [Abstract][Full Text] [Related]
16. Alterations of the central noradrenergic system in MPTP-induced monkey parkinsonism.
Miyoshi R; Kito S; Ishida H; Katayama S
Res Commun Chem Pathol Pharmacol; 1988 Oct; 62(1):93-102. PubMed ID: 2849789
[TBL] [Abstract][Full Text] [Related]
17. Dopamine in the extrapyramidal motor function. A study based upon the MPTP-induced primate model of parkinsonism.
Chiueh CC
Ann N Y Acad Sci; 1988; 515():226-38. PubMed ID: 3259118
[No Abstract] [Full Text] [Related]
18. Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus.
Mitchell IJ; Cross AJ; Sambrook MA; Crossman AR
Neurosci Lett; 1985 Oct; 61(1-2):195-200. PubMed ID: 3878482
[TBL] [Abstract][Full Text] [Related]
19. Antiparkinsonian and behavioral effects of inactivation of the substantia nigra pars reticulata in hemiparkinsonian primates.
Wichmann T; Kliem MA; DeLong MR
Exp Neurol; 2001 Feb; 167(2):410-24. PubMed ID: 11161630
[TBL] [Abstract][Full Text] [Related]
20. Injury of nigral neurons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a tyrosine hydroxylase immunocytochemical study in monkey.
Kitt CA; Cork LC; Eidelberg F; Joh TH; Price DL
Neuroscience; 1986 Apr; 17(4):1089-103. PubMed ID: 2872615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
